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iabetes and Heart Failure
he Role of Thiazolidinediones in
anaging These Partners in Crime*
arl V. Leier, MD, FACC,
arrie J. Haas, MD, FACC
olumbus, Ohio
ver 30 years ago, data from the Framingham cohort
stablished a link between diabetes mellitus (DM) and heart
ailure (HF) (1). Most HF trials have since shown a 25% to
5% prevalence of DM in HF populations. Diabetes mel-
itus is associated with an increased mortality and hospital
eadmission rate in patients with HF, and uncontrolled DM
nd hyperglycemia reduce the effectiveness of standard HF
herapies (2,3). The increasing age and the obesity epidemic
n our society are increasing the incidence and prevalence of
oth DM and HF.
See page 32
Diabetes mellitus is a major risk factor for the develop-
ent of HF through its propagation of atherosclerotic
ardiovascular disease, diabetic cardiomyopathy, and ne-
hropathy. Diabetes mellitus and hyperglycemia evoke lipid
isorders, endothelial dysfunction, platelet hyperreactivity,
n elevation of proinflammatory cytokines, circulating free
atty acids and adhesion molecules, and oxidative stress of
yocardium. These derangements must adversely affect the
athophysiology and clinical course of HF. However, their
mpact does not simply begin with established DM. Pre-
iabetes–insulin resistance itself is associated with left ven-
ricular (LV) dysfunction, HF, and increased cardiovascular
ortality (4–6). Each 1% elevation of glycosylated hemo-
lobin (HbA1c) can be linked to an 8% increased risk of
F, and hyperglycemia over time increases HF symptoms.
eart failure itself engenders insulin resistance, and in turn,
he insulin resistance adversely affects HF and fosters HF as
n atherogenic condition (7–10).
Thiazolidinediones (TZDs) reverse or ameliorate many
f the adverse cardiovascular effects of DM (11–13). The
ZDs increase insulin sensitivity, enhance glucose control,
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.p
From the Division of Cardiovascular Medicine, The Ohio State University of
edicine and Public Health, Columbus, Ohio.mprove the lipid profile, suppress inflammatory and car-
iovascular risk markers, reduce proinflammatory cytokines,
ugment endothelial function, and improve vascular
tructure and function. The TZDs now have been shown
o substantially reduce the development of DM in pa-
ients with prediabetes (14). They decrease mortality,
troke, and myocardial infarction rates in patients with
ype II DM (15).
These favorable properties should make TZDs ideal for
he management of patients with both DM and HF.
owever, case reports and a number of retrospective studies
ave raised concern that TZDs exacerbate clinical HF
16–20).
The TZDs, like many antihyperglycemic agents, increase
ody weight during long-term administration. The added
eight produced by TZDs is secondary to an increase in
eripheral obesity (but less visceral fat) and fluid volume. In
eneral DM populations, monotherapy with TZDs is asso-
iated with a net 3% to 5% incidence of pedal edema and a
et 1% incidence of clinical HF (18). When combined
ith other oral antihyperglycemic agents, the incidence of
edal edema increases to 6% to 8% (1% to 3% in non–TZD-
reated patients), and with a further increase to 13% to 17%
n patients concomitantly treated with insulin (4% to 7% in
on-TZD insulin-treated patients) (18). The mechanism of
ZD-induced edema has not been convincingly established.
Pedal edema is often a multifactorial process, not neces-
arily attributable to HF alone. From an insurance database,
elea et al. (16) reported an adjusted incidence of develop-
ng clinical HF of 8.2% in patients when TZDs were added
o other DM therapy versus 5.3% in those continued on
imilar therapy without TZDs, a net incidence of 2.9% over
he 40-month study period. Although adjusted for analyses,
he patients in the TZDs group had a higher prevalence of
nderlying (pre-TZDs) problematic coronary artery disease,
iabetic complications, insulin therapy, and other comor-
idities. Judging from the higher background use of
ngiotensin-converting enzyme inhibitors and beta-
locking agents in the TZDs group, it is likely that
nrecognized or unrecorded HF or systemic hypertension
lso were more prevalent in the TZD treatment group.
sing a Kaiser Permanente database, Karter et al. (21)
eported that initiating monotherapy for DM with TZDs
id not increase hospitalization rate for HF over a mean
ollow-up period of 10.2 months compared with initiating
ulphonylureas or insulin.
The biggest challenge for the safe use of TZDs in DM
esides in the patients with concomitant HF. A retrospec-
ive study by Tang et al. (17) showed that 17.1% (19 of 111)
f their patients with both DM and systolic HF (LVEF
45%, New York Heart Association functional class
NYHA FC] I to III) experienced weight gain plus pedal
dema, 5.4% (6 of 111) developed jugular venous distention,
nd 1.8% (2 of 111) showed clinical or radiographic signs of
ulmonary edema while on TZD therapy. Echocardio-
g
o
a
a
b
(
t
t
s
C
p
a
t
b
r
a
i
0
w
T
r
K
p
H
a
e
d
m
r
t
p
t
h
i
a
a
r
c
v
e
e
N
N
s
h
e
s
u
i
s
d
t
e
p
t
t
a
r
t
(
i
b
r
A
k
a
t
r
a
t
p
i
R
s
O
4
R
1
1
1
1
38 Leier and Haas JACC Vol. 50, No. 1, 2007
Editorial Comment July 3, 2007:37–9raphic testing in this study did not uncover adverse effects
f TZDs on cardiac function. Data from larger studies
ppear more benign. From a Medicare database, Inzucchi et
l. (21) found that TZDs over 1 year resulted in only a
orderline increase in the risk of hospitalization for HF
hazard ratio [HR] 1.09, 95% confidence interval [CI] 1.00
o 1.20) in elderly diabetic patients after myocardial infarc-
ion. The TZDs did not impact mortality in this study. A
imilarly low rehospitalization risk for HF (HR 1.06, 95%
I 1.00 to 1.09) was found by Masoudi et al. (22) in elderly
atients with both DM and HF; interestingly, TZDs were
ssociated with a lower risk of death (HR 0.87, 95% CI 0.80
o 0.94) at 1 year. And now, in over 4,500 outpatients with
oth DM and HF in the Veterans Administration database
eported by Aguilar et al. (23) in this issue of the Journal,
mbulatory DM-HF patients did not experience an increase
n hospitalization rate (covariate adjusted HR 1.00, 95% CI
.81 to 1.24) or mortality (HR 0.98, 95% CI 0.81 to 1.17)
hen treated with TZDs compared with those not receiving
ZDs.
The authors of this editorial were pleased to see the
esults of the Aguilar et al. (23) study, along with those of
arter et al. (21) and Masoudi et al. (22), because we have
rescribed TZDs in diabetic HF patients with the view that
F therapy is more effective when DM is better controlled,
nd that the cumulative beneficial effects of TZDs over time
xceed their major shortcoming (other than cost), namely
etectable fluid retention in10% of HF patients. Further-
ore, problematic fluid retention by TZDs is readily
eversed by discontinuing the TZDs or reasonably con-
rolled by those experienced with HF management. Simple
edal edema without problematic intravascular fluid reten-
ion is even less of a threat; never in the history of mankind
ave we ever lost someone to pedal edema alone.
There is still a dearth of data relative to the use of TZDs
n diabetic HF patients. Interpretable data are mostly
vailable for NYHA FC I to II patients. All studies to date
re retrospective, gleaned from database information. Most
eports placed emphasis on safety rather than potential
ardiovascular benefits; in contrast to monitoring the ad-
erse effects of TZDs, the identification of beneficial clinical
ffects and outcomes are likely to require studies of consid-
rably longer duration and greater complexity. Studies in
YHA FC III patients are limited at best. Studies in
YHA FC IV patients could be of interest, but have a low
ales potential to inspire industrial support. In addition, it is
ard to imagine how TZDs could favorably impact the
xtreme mechanisms and dire clinical status of this patient
ubgroup during their typical short-term existence.
Because HF itself evokes insulin resistance, it is not
nreasonable to suggest that TZDs be studied prospectively
n non-DM NYHA FC I to III HF patients. Furthermore,
hould TZDs be considered for primary prevention of heart
isease and HF in prediabetic subjects who have not yet met
he criteria for the diagnosis of DM and the standard
ligibility for antihyperglycemic therapy? In such a patientopulation, the results of the DREAM (Diabetes REduc-
ion Assessment with ramipril and rosiglitazone Medica-
ion) trial (14) showed that rosiglitazone at 8 mg daily over
median follow-up of 3 years reduced the relative occur-
ence of DM by 60% and achieved normoglycemia in 70%
o 80% at a net risk of developing clinical HF in only 0.4%
TZDs 0.5%, placebo 0.1%). Parenthetically, hypoglycemia
s an uncommon adverse effect of TZDs when not com-
ined with other antihyperglycemic therapy. Until the
esults of prospective trials are available, the report of
guilar et al. (23) and others noted above should at least
eep TZDs out of the dreaded “black box” warning for HF,
nd even raise the question of whether we should expand
he clinical application of TZDs in LV dysfunction and HF
ather than limit or restrict such. Using a manageable
dverse property occurring in 10% of recipients to deny
he beneficial effects of TZDs in the remaining 90% (and
erhaps in many of the 10% group as well) is not shrouded
n wisdom.
eprint requests and correspondence: Dr. Carl V. Leier, Divi-
ion of Cardiovascular Medicine, Davis HLRI, 2nd Floor, The
hio State University, 473 West 12th Avenue, Columbus, Ohio
3210. E-mail: carl.leier@osumc.edu.
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